A 50-year-old woman with cowden syndrome and joint pains

Arthritis Care and Research

Volumn 67, Issue 11, 2015, Pages 1604-1608

  Sagar, Vinay ^a   Bond, Jeffrey R ^a   Chowdhary, Vaidehi R ^a  

^a Mayo Clinic   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYCHLOROQUINE; LEFLUNOMIDE; METHOTREXATE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PREDNISOLONE; PREDNISONE; PROTEIN SERINE THREONINE KINASE;

ADULT; ARTHRALGIA; CASE REPORT; CONFERENCE PAPER; COWDEN SYNDROME; DIAGNOSTIC IMAGING; DIARRHEA; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; FEMALE; GASTROINTESTINAL SYMPTOM; GENE MUTATION; GENETIC DISORDER; GENETIC SCREENING; HUMAN; LABORATORY TEST; METACARPOPHALANGEAL JOINT; METATARSOPHALANGEAL JOINT; MIDDLE AGED; MORNING STIFFNESS; PHYSICAL EXAMINATION; PROXIMAL INTERPHALANGEAL JOINT; RHEUMATOID ARTHRITIS; RHEUMATOLOGY; TENDINITIS; TENOSYNOVITIS; ARTHRITIS; COMPLICATION; CONGENITAL TUMOR; DIFFERENTIAL DIAGNOSIS; RADIOGRAPHY;

ARTHRALGIA; ARTHRITIS; DIAGNOSIS, DIFFERENTIAL; FEMALE; HAMARTOMA SYNDROME, MULTIPLE; HUMANS; MIDDLE AGED;

EID: 84945333827     PISSN: 2151464X     EISSN: 21514658     Source Type: Journal    
DOI: 10.1002/acr.22616     Document Type: Conference Paper

References (24)

1. Pilarski R, Burt R, Kohlman W, Pho L, Shannon KM, Swisher E., Cowden syndrome and the PTEN hamartoma tumor syndrome: systematic review and revised diagnostic criteria. J Natl Cancer Inst 2013; 105: 1607-16.
2. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO III, et al., 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 2010; 62: 2569-81.
3. Govindarajan V, Agarwal V, Aggarwal A, Misra R., Arthritis in sarcoidosis. Assoc Physicians India 2001; 49: 1145-7.
4. Raizis AM, Ferguson MM, Robinson BA, Atkinson CH, George PM., Identification of a novel PTEN mutation (L139X) in a patient with Cowden disease and Sjögren's syndrome. Mol Pathol MP 1998; 51: 339-41.
5. Heindl M, Handel N, Ngeow J, Kionke J, Wittekind C, Kamprad M, et al., Autoimmunity, intestinal lymphoid hyperplasia, and defects in mucosal B-cell homeostasis in patients with PTEN hamartoma tumor syndrome. Gastroenterology 2012; 142: 1093-6.
6. Pinzone JJ, Eng C, Paik J, Brindle KA, Ringel MD, Katz JD., A novel PTEN mutation in Cowden syndrome is associated with a mixed degenerative-erosive arthritic process: potential molecular pathogenic mechanisms. Am J Med Genet A 2007; 143A: 1522-7.
7. Patel RK, Mohan C., PI3K/AKT signaling and systemic autoimmunity. Immunol Res 2005; 31: 47-55.
8. Di Cristofano A, Kotsi P, Peng YF, Cordon-Cardo C, Elkon KB, Pandolfi PP., Impaired Fas response and autoimmunity in Pten+/- mice. Science 1999; 285: 2122-5.
9. Podsypanina K, Ellenson LH, Nemes A, Gu J, Tamura M, Yamada KM, et al., Mutation of Pten/Mmac1 in mice causes neoplasia in multiple organ systems. Proc Natl Acad Sci U S A 1999; 96: 1563-8.
10. Jones RG, Elford AR, Parsons MJ, Wu L, Krawczyk CM, Yeh WC, et al., CD28-dependent activation of protein kinase B/Akt blocks Fas-mediated apoptosis by preventing death-inducing signaling complex assembly. J Exp Med 2002; 196: 335-48.
11. Borlado LR, Redondo C, Alvarez B, Jimenez C, Criado LM, Flores J, et al., Increased phosphoinositide 3-kinase activity induces a lymphoproliferative disorder and contributes to tumor generation in vivo. FASEB J 2000; 14: 895-903.
12. Shrestha S, Yang K, Guy C, Vogel P, Neale G, Chi H., Treg cells require the phosphatase PTEN to restrain TH1 and TFH cell responses. Nat Immunol 2015; 16: 178-87.
13. Huynh A, DuPage M, Priyadharshini B, Sage PT, Quiros J, Borges CM, et al., Control of PI(3) kinase in Treg cells maintains homeostasis and lineage stability. Nat Immunol 2015; 16: 188-96.
14. Hawkes D, Benhamu J, Sidwell T, Miles R, Dunlop RA., Revisiting adverse reactions to vaccines: a critical appraisal of autoimmune syndrome induced by adjuvants (ASIA). J Autoimmun 2015; 59: 77-84.
15. Westra J, Rondaan C, van Assen S, Bijl M., Vaccination of patients with autoimmune inflammatory rheumatic diseases. Nat Rev Rheumatol 2015; 11: 135-45.
16. Adverse effects of vaccines: evidence and causality. In:, Stratton K, Ford A, Rusch E, Clayton EW, editors. Washington (DC): National Academy of Sciences; 2011.
17. Suarez-Fueyo A, Barber DF, Martinez-Ara J, Zea-Mendoza AC, Carrera AC., Enhanced phosphoinositide 3-kinase δ activity is a frequent event in systemic lupus erythematosus that confers resistance to activation-induced T cell death. J Immunol 2011; 187: 2376-85.
18. Xu H, He Y, Yang X, Liang L, Zhan Z, Ye Y, et al., Anti-malarial agent artesunate inhibits TNF-α-induced production of proinflammatory cytokines via inhibition of NF-B and PI3 kinase/Akt signal pathway in human rheumatoid arthritis fibroblast-like synoviocytes. Rheumatology (Oxford) 2007; 46: 920-6.
19. Lee T, Le EN, Glass DA II, Bowen CD, Dominguez AR., Systemic lupus erythematosus in a patient with PTEN hamartoma tumour syndrome. Br J Dermatol 2014; 170: 990-2.
20. Singh N, Birkenbach M, Caza T, Perl A, Cohen PL., Tuberous sclerosis and fulminant lupus in a young woman. J Clin Rheumatol 2013; 19: 134-7.
21. Wu XN, Ye YX, Niu JW, Li Y, Li X, You X, et al., Defective PTEN regulation contributes to B cell hyper-responsiveness in systemic lupus erythematosus. Sci Transl Med 2014; 6: 246ra99.
22. Fernandez D, Bonilla E, Mirza N, Niland B, Perl A., Rapamycin reduces disease activity and normalizes T cell activation-induced calcium fluxing in patients with systemic lupus erythematosus. Arthritis Rheum 2006; 54: 2983-8.
23. Fernandez DR, Telarico T, Bonilla E, Li Q, Banerjee S, Middleton FA, et al., Activation of mammalian target of rapamycin controls the loss of TCRΖ in lupus T cells through HRES-1/Rab4-regulated lysosomal degradation. J Immunol 2009; 182: 2063-73.
24. Lai ZW, Hanczko R, Bonilla E, Caza TN, Clair B, Bartos A, et al., N-acetylcysteine reduces disease activity by blocking mammalian target of rapamycin in T cells from systemic lupus erythematosus patients: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2012; 64: 2937-46.